Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — Non-Deal Roadshow (November 2023)
102 slides from Coloplast A/s Class B's roadshow presentation, November 2023
Slide 1: Roadshow presentation FY 2022/23
Roadshow presentation FY 2022/23 Jurgen Ostomy Care user Making life easier Strive25: Sustainable Growth Leadership
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: Solid FY 22/23 result with broad-based organic growth of 8% and 28% EBIT margin
Solid FY 22/23 result with broad-based organic growth of 8% and 28% EBIT margin1, impacted by higher input costs Revenue growth FY 2022/23 highlights Reported revenue (mDKK) Organic growth • Organic growth of 8% (8% in Q4) and reported growth in DKK of 9%. Acquired growth contributed 3%-pts to repor
Slide 4: Strategic highlights from Strive25 – Sustainable growth leadership
Strategic highlights from Strive25 – Sustainable growth leadership Growth Innovation US Ostomy Care Luja™, a new male intermittent catheter with a Micro-hole Zone Technology • Advanced our competitive position, market share increased to 15-20% from ~15% • Launched in six markets with positive feedba
Slide 5: FY 2022/23 organic growth of 8% was broad-based
FY 2022/23 organic growth of 8% was broad-based and driven by a solid year in Chronic Care, despite low single-digit growth in China FY 2022/23 revenue by business area FY 2022/23 revenue by geography Business Reported revenue Organic growth Share of organic Geographic Reported revenue Organic growt
Slide 6: Strong Q4 in Ostomy Care with broad-based growth of 9%
Strong Q4 in Ostomy Care with broad-based growth of 9% and double-digit growth in China. FY 2022/23 organic growth was 8% Ostomy Care performance Q4 and FY 2022/23 highlights • Q4 organic growth was 9% and reported growth was 2% • All regions contributed to growth, with strong Q4 in Emerging markets
Slide 7: Continence Care grew 6% in Q4
Continence Care grew 6% in Q4, driven by Intermittent Catheters, while sales of Collecting Devices declined. FY 2022/23 organic growth was 7% Continence Care performance Q4 and FY 2022/23 highlights • Q4 organic growth was 6% and reported growth decreased 1% • All regions contributed to growth in th
Slide 8: Strong Q4 in Voice & Respiratory Care with 13% growth
Strong Q4 in Voice & Respiratory Care with 13% growth driven by both Laryngectomy and Tracheostomy. 2022/23 organic growth was 10%1 Voice & Respiratory Care performance Q4 and FY 2022/23 highlights • Q4 organic growth was 13% and reported growth was 10% • Continued good momentum and some benefit fro
Slide 9: Advanced Wound Care grew 8% in Q4
Advanced Wound Care grew 8% in Q4 with strong contribution from Europe and a good quarter in China. FY 2022/23 organic growth of 7% Advanced Wound Care performance Q4 and FY 2022/23 highlights • Q4 organic growth was 8% and reported growth was 13%. Advanced Wound 14 13 Dressings in isolation grew 12
Slide 10: Interventional Urology grew 5% driven by Men’s Health
Interventional Urology grew 5% driven by Men’s Health, partly offset by a high baseline and order phasing. FY 2022/23 organic growth of 10% Interventional Urology performance Q4 and FY 2022/23 highlights • Q4 organic growth was 5%, against a high baseline last year. Reported growth was 0% 23 • Growt
Slide 11: 2022/23 reported revenue grew 9%
2022/23 reported revenue grew 9%, with ~3%-points from acquisitions, mostly Atos Medical, and ~2%-points negative impact from currencies FY 2022/23 Revenue development (mDKK) FY 2022/23 highlights • Reported revenue increased by DKK 1,921 million or 9% vs. last year • Organic growth was 8% or DKK 1,
Slide 12: FY 2022/23 reported EBIT margin of 28%
FY 2022/23 reported EBIT margin of 28%1, reflecting inflationary headwind on input costs and an increase in operating expenses FY 2022/23 EBIT margin development before special items (%) FY 2022/23 highlights • Gross margin was 67%, against 69% last year • Negative impact from: raw material price in
Slide 13: Adj. FCF in FY was DKK 3,749 million
Adj. FCF in FY was DKK 3,749 million. Operating cash flow impacted by higher income tax paid, interest payments, and higher working capital FCF development1 FY 2022/23 highlights • Free cash flow for FY 2022/23 was an outflow of DKK 4,731 million compared to an outflow of DKK 6,660 million last year
Slide 14: FY 2023/24 guidance – organic growth of around 8%
FY 2023/24 guidance – organic growth of around 8% and reported EBIT margin of 27-28%1 GUIDANCE 2023/24 GUIDANCE (DKK)* KEY ASSUMPTIONS • Growth across business areas and regions largely in line with Strive25 ambitions, except for China • China Ostomy Care – improvement in growth, but below double-di
Slide 15: FY 2023/24: continued good growth momentum; easing of inflationary headwinds
FY 2023/24: continued good growth momentum; easing of inflationary headwinds and 1%-p EBIT margin dilution from Kerecis Revenue growth assumptions Key impacts on gross- and EBIT margin development in 2023/24 ILLUSTRATIVE FY 2023/24 organic growth expected at ~68% around 8% in constant currencies ~67
Slide 16: Making it easier to be yourself
Making it easier to be yourself Leading intimate healthcare Introduction to Coloplast Jurgen | OC user
Slide 17: Coloplast has five business areas all with global sales presence
Coloplast has five business areas all with global sales presence Group revenue 2022/23 by segment1 Group revenue 2022/23 by geography 1 Continence Care 1 32% European Ostomy Care markets 37% 57% Other developed markets DKK DKK 26% 24.5bn 4 24.5bn Interventional Urology 11% 1 Emerging Voice & 5 marke
Slide 18: Coloplast specializes in intimate healthcare needs
Coloplast specializes in intimate healthcare needs Who are our typical users How do we help them? Our brands Ostomy Care People who have had a part of their Adhesive ostomy bags SenSura® Mio digestive or urinary system redirected to an Supporting products Brava® opening in the abdominal wall Contine
Slide 19: The Chronic Care model secures a predictable revenue stream
The Chronic Care model secures a predictable revenue stream and stable revenue growth The chronic care user flow Chronic Care condition New user Installed base of users Stable flow of loyal users Solid reimbursement Coloplast group revenues Revenue (DKK bn) Organic growth (%) 10 9 8 8 8 8 8 7 6 7 6
Slide 20: Intimate healthcare is characterized by stable industry trends
Intimate healthcare is characterized by stable industry trends 01. 01. Demographics Surgical and medical trends Growing elderly population Earlier detection and cure, increases customer base for eventually reduces addressable Coloplast products market for Coloplast treatment Limiters Drivers product
Slide 21: Coloplast has strong market positions in Europe and great commercial potential outside Europe
Coloplast has strong market positions in Europe and great commercial potential outside Europe Europe Other developed Emerging Ostomy Continence Voice & Respiratory Interventional Advanced 1 1 1 4 5 1 Global market position Care Care Care (Laryngectomy) Urology Wound Care Addressable market 41-44bn 2
Slide 22: We are building the consumer healthcare company of the future
We are building the consumer healthcare company of the future Macro Trends Impact Commercial model Ageing population Healthcare consumerism Digital transformation Price pressure Channel consolidation 22
Slide 23: Our Strive25 strategy supports continued long-term value creation
Our Strive25 strategy supports continued long- term value creation through revenue and earnings growth Long-term financial guidance 8-10% more than 30% organic growth EBIT margin p.a.1 beyond 2024/252 1 Raised to 8-10%, from previously 7-9%, on July 7 as a result of the acquisition of Kerecis, expec
Slide 24: Organic growth acceleration in the outer part of the Strive25 period
Organic growth acceleration in the outer part of the Strive25 period and beyond through a balanced mix of organic and inorganic initiatives 8-10% ~8% Strive25 Strive25 +1%-point ambition: ambition: accretion from Double-digit Launch of the FY 2024/25 organic growth Clinical above the market Performa
Slide 25: Strive25 emphasis on improving environmental performance
With Strive25 we put emphasis on improving our environmental performance, while continuing our ongoing commitments Our mission Making life easier for people with intimate healthcare needs Our 2025 priority Our 2025 priority Improving products Reducing emissions and Packaging1 90% of packaging recycl
Slide 26: Yearly incremental investments of up to 2% of revenue
We will continue to support organic growth through yearly incremental investments of up to 2% of revenue in the Strive25 period We expect to invest Key Investment Decision Drivers Key Investment Areas – up to 2% of revenue in incremental OPEX investments Investments made in H1 of Strive25 Continued
Slide 27: Strive25: M&A plays a bigger role
Strive25: M&A plays a bigger role as we seek to secure long-term growth and value creation options beyond 2025 Opportunity Systematic based screening Large plays Channel expansion Portfolio expansion Early-stage & adjacencies technologies Examples: 2022 US direct-to-consumer TFL Drive DME dealers1 (
Slide 28: Key enablers to support the commercial model in Chronic Care
We have built key enablers to support the commercial model in our Chronic Care businesses Commercial model Key enablers Coloplast® Care Superior, clinically differentiated products Direct to Consumer Consumer Clinical Direct Businesses preference Data and digital tools preference Data & Digital tool
Slide 29: Direct business in Chronic Care drives improved outcomes
Direct business in Chronic Care serving consumers drives improved outcomes and is a vital component of our growth Direct presence in top 5 markets and strategic rationale Coloplast Consumer presence (incl. patient support programme, Coloplast® Care) Control and continuity 1 of product supply ~30% MS
Slide 30: Clinical Performance Programme to tackle the biggest issues users face
We have initiated a very ambitious Clinical Performance Programme to tackle the biggest issues users face Continence Care - preventing UTIs remains one of the biggest unmet needs Ostomy Care - Leakage remains the biggest challenge for our users 45 % of users describe UTIs as their greatest challenge
Slide 31: Luja™ with Micro-hole Zone Technology addresses key UTI risk factors
Luja™, our new catheter platform with Micro-hole Zone Technology™ addresses key UTI risk factors UTI Risk Factor Model1 UTI risk factors addressed by Luja™ Intermittent General patient catheterisation conditions UTI risk factor: UTI risk factor: Non-hygienic technique Urethral trauma UTI risk factor
Slide 32: Comprehensive clinical program behind Luja™
Comprehensive clinical program behind Luja™ to demonstrate the clinical relevance and difference Pivotal studies 2 multinational pivotal studies2 involving 110+ users demonstrating the impact on the key risk factors of UTIs Pilot studies Multicenter, randomised cross 8 studies comparing Luja vs. ove
Slide 33: Data on Heylo™ is promising
Data on Heylo™ is promising. First pivotal clinical study showed improvement in quality of life and a 31% reduction in leakage Pre-pilot study on Heylo Pivotal clinical studies on Heylo Product performance & user experience1 First pivotal clinical study on Heylo4, conducted in Germany showed: Using
Slide 34: Profitability supported by scalability and efficiency gains
Profitability supported by scalability and efficiency gains enabling additional innovation and commercial investments Gross Profit development, % Cost item Development, in % of revenue* FY 22/23 Gross Profit negatively impacted by inflationary headwind on input costs (raw materials, energy, labour)
Slide 35: Global Operations Plans (GOPs) have delivered significant value since 2008
Global Operations Plans (GOPs) have delivered significant value since 2008, supporting Coloplast’s industry leading profitability 2008 2009 2012 2017 2020 2023-2026 Turn-around GOP1 GOP2/GOP3 GOP4 GOP5 GOP6 Focused Operational Operational Step change Fit for the future Excellence Excellence executio
Slide 36: GOP5 focused on automation, procurement and scale
GOP5 focused on automation, procurement and scale. With continued pressure on input costs, procurement remains a key topic in GOP6 1. Automation to mitigate growth in blue-collar FTE # of FTE release through automation Realised 1,000 • Due to longer component lead times, 8% Planned 600 the release o
Slide 37: GOP6 will drive continued efficiency improvements
GOP6 will support Coloplast’s growth agenda and drive continued efficiency improvements to support EBIT margin ambition Optimize footprint Drive efficiencies in procurement • New manufacturing site of 30,000 m2 in Portugal • Company-wide procurement programme initiated, aimed at driving • Portugal s
Slide 38: A global Business Support and IT landscape enables Coloplast to scale
A global Business Support and IT landscape enables Coloplast to scale faster and efficiently and integrate Atos Medical into the Group Global Business Services Global business services handle the majority of all global support % of group processes 100% ~90% 100% 100% IT infrastructure Finance / acco
Slide 39: EBIT margin development is a function of growth, scalability, cost discipline
EBIT margin development continues to be a function of growth, scalability, cost discipline and investment activity EBIT margin (%) Illustrative Future drivers of EBIT margin EBIT will be positively impacted by: Leverage effect on fixed costs e.g. >30% distribution, admin and R&D costs especially dri
Slide 40: Continued strong development in free cash flow
Continued strong development in free cash flow during the Strive25 strategy period Taxation Net working capital CAPEX2 Reported tax rate Net working capital, % of revenue CAPEX DKKm Depreciation and amortisation, % of revenue CAPEX, % of revenue 5% 5% 5% 5% ~5% 6% 4% 5% 4% 4% 4% 4% 4% 25% 26% 23% 24
Slide 41: We will continue to provide attractive cash returns
We will continue to provide attractive cash returns despite investments in commercial activities and the Atos Medical and Kerecis acquisitions Coloplast cash distribution to investors Highlights Dividends paid out in the year (DKKm) (1) Share buy-back (DKKm) Pay-out ratio (%) (2) • Coloplast returns
Slide 42: In sum, Coloplast can continue to deliver stable shareholder returns
In sum, we believe Coloplast can continue to deliver stable shareholder returns through ... Organic growth and EBIT margin Highlights 28% • Stable market trends in our Chronic Care business • Innovative product portfolio and new product launches 12% 8% • Strong Coloplast Care retention program and i
Slide 43: Introduction to Kerecis
Introduction to Kerecis An emerging category leader in the biologics wound care segment
Slide 44: With Kerecis, Coloplast adds a long-term growth business
With Kerecis, Coloplast adds a long-term growth business, uniquely positioned to support long-term value creation Compelling strategic rational Kerecis financial assumptions Performance of Kerecis • Three-year revenue CAGR of ~30% until FY 2025/26 • Attractive gross margin level, accretive to Colopl
Slide 45: We enter the biologics segment
We enter the biologics segment, expanding our footprint in the US and transforming our presence in the global advanced wound care market Addressable advanced wound care market by segment Addressable advanced wound care market Gelling (advanced dressings and biologics) Fibers 2 Advanced 3-5 With Kere
Slide 46: Kerecis is transforming wound healing with fish-skin technology
Kerecis is transforming wound healing with its clinically differentiated technology platform based on gently processed fish skin Kerecis key business highlights Started in 2009, with headquarters and manufacturing in Iceland 1 DKK 772m Revenue for FY 2022/23 Proprietary product platform based on int
Slide 47: Fish skin – uniquely positioned for wound healing in humans
Fish skin – uniquely positioned for wound healing in humans Kerecis fish-skin technology – gently processed, preserving its similarity to human skin Fish Skin for Human Skin* Epidermis Dermis 100 µm 100 µm Advantages of the fish-skin technology: • High resemblance to human skin: similar three-dimens
Slide 48: Sustained strong growth momentum through proven commercial model
Sustained strong growth momentum through proven commercial model and a purpose-driven organisation Kerecis revenue distribution, FY22/23 Sustained strong growth through: By wound type: By care setting: By geography: • Continued strong growth in the US across wound types and care settings Burn Hospit
Slide 49: Introduction to Atos Medical (Voice and Respiratory Care)
Introduction to Atos Medical (Voice and Respiratory Care) The global market leader in laryngectomy Joakim | Provox Life user
Slide 50: Atos Medical is the market leader in the chronic laryngectomy market
Atos Medical is the market leader in the attractive chronic laryngectomy market, with strong growth and profitability outlook Key market and business highlights Key financial assumptions Laryngectomy Tracheostomy • Organic growth 8-10% Procedures per year ~50,000 ~1,000,000 Organic growth • Laryngec
Slide 51: Atos improves the lives of patients following Total Laryngectomy procedures
Atos improves the lives of patients following Total Laryngectomy procedures A Total Laryngectomy is a non-elective After surgery, a Voice Prosthesis (VP) is inserted by a healthcare professional, surgery performed in the advanced and the patient applies the Heat- and Moisture Exchanger (HME) and adh
Slide 52: Significant untapped potential in the laryngectomy market
There is significant untapped potential in the laryngectomy market today, which we will seek to eliminate The laryngectomy market, DKKbn Low level of market penetration due to: We will eliminate the ‘white space’ by: Lack of clinical standards in existing 01 markets outside of Northern Europe Settin
Slide 53: Tracheostomy patients have similar needs as Laryngectomy patients
Tracheostomy patients have similar needs as Laryngectomy patients, as they are both breathing through a neck stoma A Tracheostomy is a surgical The Tracheostomy patient journey starts with a cannula insertion, which can be procedure that creates an opening in reversed at any stage the neck for direc
Slide 54: Appendices
Leading intimate healthcare Leading intimate healthcare Appendices Laura | MS user
Slide 55: The Coloplast share
The Coloplast share (COLO-B.CO) Holders of A shares and family 1 Danish institutions Foreign institutions Coloplast A/S Coloplast share listed on Nasdaq Copenhagen Other shareholders since 1983 Non-registered shareholders 2.0% 6.0% ~173.2 billion DKK (~25 billion USD) market 2.0% cap @ ~771.0 DKK pe
Slide 56: Capital structure
Capital structure Comments Net interest-bearing debt • Overall policy is that excess liquidity is returned to shareholders through a combination of dividends and 2.3x 2.4x 2.0x share buy-backs • Bi-annual dividends 18,091 18,660 • Share buy-backs of DKK 500m per year 0.3x 1.0x expected, no buy-back
Slide 57: Solid Q4 with organic growth of 8%
Solid Q4 with organic growth of 8% driven Chronic Care with a strong quarter in Ostomy Care and double-digit growth in China, as expected Q4 2022/23 revenue by business area Q4 2022/23 revenue by geography Business Reported revenue Organic growth Share of organic Geographic Reported revenue Organic
Slide 58: Reported revenue grew 3% in Q4
Reported revenue grew 3% in Q4, reflecting solid organic growth of 8% and significant headwind from exchange rate developments Q4 2022/23 Revenue development (DKKm) Q4 2022/23 highlights • Organic growth was 8% or DKK 470 million, driven by: 167m DKK • Continued good momentum across regions in Chron
Slide 59: Reported EBIT margin of 28% in Q4
Reported EBIT margin of 28%1 in Q4, reflecting mostly inflationary headwind on input costs and significant negative impact from currencies Q4 2022/23 EBIT margin development before special items (%) Q4 2022/23 highlights • Gross margin was 66%, against 69% in Q4 last year 29.9 -2.5 2.4 29.9 • Signif
Slide 60: Key value ratios
Key value ratios Profitability drivers Free Cash Flow drivers 32.7 33.4 36.2 36.8 32.3 32.0 31.5 34.7 34.6 34.7 31.2 32.3 30.1 30.7 28.7 29.0 28.7 28.2 26.1 26.3 23.4 23.6 23.4 23.7 4.0 4.2 4.1 3.9 4.5 4.6 5.0 5.2 5.0 5.1 4.1 3.5 3.9 3.9 3.8 3.9 3.8 3.6 17/18 18/19 19/20 20/21 21/22 22/23 17/18 18/1
Slide 61: Coloplast revenue development by business area
Coloplast revenue development by business area Ostomy Care Interventional Urology Voice & Respiratory Care* 8 10 8 6 6 19 16 Contribution to reported growth 6%-points 3%-points 7 5 4 7 5 13 10 10 14 Organic growth (8 months) 10% 8,620 9,024 9 10 7,538 7,841 7,166 -7 -7 2,424 2,674 1,970 1,835 2,097
Slide 62: Coloplast revenue development by geography and total
Coloplast revenue development by geography and total Europe Other Developed Markets 6 15 8 2 4 16 21 6 8 12 6 2 4 5 5 9 11 5 6 13,908 3 12,916 6,480 10,573 10,820 11,261 5,775 4,380 4,644 4,785 18/19 19/20 20/21 21/22 22/23 18/19 19/20 20/21 21/22 22/23 FY 21/22 and FY 22/23 reported growth rates in
Slide 63: Segment operating profit
Segment operating profit Segment Operating Profit DKKm (Excludes shared/non-allocated costs) Segment Operating Profit Margin (%) Chronic Care Interventional Urology Voice & Respiratory Care1 Adv. Wound Dressings Biologics1 Ostomy and Continence Care 58 58 57 58 58 37 36 35 35 36 38 39 37 38 35 36 37
Slide 64: FY 2022/23 Atos Medical and Kerecis PPA amortisation impact on EBIT margin
FY 2022/23 Atos Medical and Kerecis PPA amortisation impact on EBIT margin 32% 3% 29% 29% 28% 0% 28% 1% 0% DKK 74 DKK 219 DKK 115 DKK 735 million million million million FY 2022/23 Special items total1 EBIT margin PPA amortisation2 EBIT margin Amortisation excl. EBITA Depreciation EBITDA EBIT margin
Slide 65: Exchange rate exposure FY 2023/24 and hedging policy
Exchange rate exposure FY 2023/24 and hedging policy Revenue FX exposure 2023/241) 12 months exposure from 10% initial exchange rate drop1) Other 17% -710 EUR USD -220 34% CNY, JPY, AUD, BRL & ARS 11% -350 GBP -220 HUF 0 13% 130 GBP 25% Revenue (DKKm) EBIT (DKKm) USD Foreign exchange rate guidance f
Slide 66: US Mesh litigation – Overview of financial impact
US Mesh litigation – Overview of financial impact P&L – overview of special items related to the Mesh Balance Cash flow litigation Assets DKKbn 13/14 - 18/19 19/20 20/21 21/22 22/23 Restricted cash, DKKbn 17/18 0.5 0.5 EBIT (before special items) 5,556 5,854 6,355 6,910 6,845 Special items (Mesh) -4
Slide 67: Stable global health reforms environment
Stable global health reforms environment, expectations of long-term negative impact of up to -1% on topline unchanged Europe Rest of World • Netherlands: Reimbursement pressure on OC and CC • U.S.: Reimbursement pressure on OC and CC (Managed Care) • France: Reimbursement pressure on WC • Italy: Reg
Slide 68: CARE helps us increase retention and improve product compliance
CARE helps us increase retention and improve product compliance We co-develop CARE content with CARE is a personal and “high- Global program with shared local clinicians touch” program infrastructure Advisors available on phone Clinically validated content and call protocol - ERP Website with reliab
Slide 69: With our DtC marketing program we reach into the community
With our DtC marketing program we reach into the community We operate in numerous channels to expose our …and with the reach we get several benefits service and product offering… Introduce innovative products Ensure product accessibility Ensure successful experience 69
Slide 70: The generic model for distribution and reimbursement of our products
The generic model for distribution and reimbursement of our products Prescription & Insurance Product Reimbursement price Prescription & Insurance Payer Distribution Consumer $ Product 70
Slide 71: Interventional Urology’s revenue is balanced geographically
Interventional Urology’s revenue is balanced geographically and across the four business areas Interventional Urology at a Glance ~15% market share in global market of DKK 18-20bn market FY 22/23 growing 4-6% annually 11% Coloplast position, FY 22/23 of Coloplast sales Endourology Men’s Health Women
Slide 72: Coloplast Interventional Urology is split into four business areas
Coloplast Interventional Urology is split into four business areas Men’s Women’s Bladder health Endourology & surgery Health Health • Erectile Dysfunction • Stress Urinary Incontinence • Stone Management • Bladder Drainage • Male Incontinence (SUI) • Transurethral • Benign prostatic hyperplasia • Te
Slide 73: Strong presence in Interventional Urology but room to capture market share
We have a strong presence in our categories in Interventional Urology but there is room to capture market share 1 Men’s Health Women’s Health Endourology Bladder Health & 1 Surgery Inflatable Penile Male Stress urinary Pelvic organ Prosthesis (IPP) incontinence incontinence prolapse Fragmented Compe
Slide 74: Refined product roadmap in Interventional Urology
We are executing a refined product roadmap in Interventional Urology aligned to Strive25; progress is tracking to key milestones Strategy Description Men’s Health Women’s Health Endourology Projects that address regulatory Cadence of stone Strengthen core requirements, close gaps and maintain IPP En
Slide 75: We will deliver growth through product and therapy expansion
We will deliver growth through product and therapy expansion Tissue Fixation System Implantable Tibial Nerve TECHNOLOGY ASSESSMENT Stimulator Launched 22/23 Launch expected in 25/26 ACTIVELY PURSUING POP SUI AUS Cancer ED IU Today OAB Endo Endo Consum- ables Laser Endo Visualization Soprano® BPH Hyb
Slide 76: Acquisition of Nine Continents to enter the OAB market
With the acquisition of Nine Continents, we are executing on the option to enter the attractive OAB market with Intibia Overactive bladder (OAB) market Why Implantable Tibial Nerve Stimulation (ITNS)? Less invasive ITNS complete in single procedure +80m people globally suffer from OAB symptoms proce
Slide 77: The Wound & Skin Care 2025 strategic plan
The Wound & Skin Care 2025 strategic plan Scale our China business Build on positive momentum in EU by strengthening our commercial in silicone and 3DFit Technology and foundation and accelerate in silicone increase share of voice in selected with 3DFit Technology markets Scale our US business in Ac
Slide 78: In US Ostomy Care we continue to win across patient pathway
In US Ostomy Care we continue to win across patient pathway We have gained significant share over the last years … as we work on multiple fronts to win across the patient pathway 3-5 days >60 days ~10 years Bags & Plates acute share Acute Post-acute Community +6%-pts Patients’ first (incl. HHA) Long
Slide 79: Coloplast awarded access to Vizient and Premier GPOs
Coloplast has been awarded access to Vizient and Premier GPOs, ensuring a level playing field in ~75% of acute accounts Coloplast has been awarded access to Vizient and Premier, the two largest GPOs in the US Acute members1 Estimated Contract Contract Contract Acute share2 expiry date length type 3,
Slide 80: Sustainability - key priorities and actions
Sustainability - key priorities and actions Improving products Reducing emissions Responsible and packaging operations Why is this a key priority: Why is this a key priority: Why is this a key priority: As a manufacturer of medical products made primarily As a growing company, we are challenged by a
Slide 81: FY 22/23 progress on key sustainability ambitions
FY 22/23 progress on key sustainability ambitions Improving products and packaging Reducing emissions Responsible operations 2025 FY FY 2025 FY FY 2025 FY FY Ambition 22/23 21/22 Ambition 22/23 21/22 Ambition 22/23 21/22 100% 2.6 2.5 90% 2.0 Recyclable 72% 72% Scope 1+2 emissions Lost time injury pa
Slide 82: Ostomy Care
Introducing Key products Ostomy Care • Between 2 and 3 million people live with a stoma globally, ~2/3 in the developed markets • Up to around 300,000 stoma surgeries per year in developed markets and China Disease areas SenSura® Mio Concave SenSura® Mio Convex SenSura® Mio • Colorectal cancer (est.
Slide 83: Supporting Products
Introducing Key products Ostomy Care Supporting Products Market fundamentals Brava® Protective Seal Brava® Skin Barrier Brava® Elastic Tape • Market size of DKK ~4bn Designed for leakage and skin Reducing skin problems Elastic so it follows • Market growth of 6-8% protection without affecting adhesi
Slide 84: Continence Care
Introducing Key products Continence Care • Intermittent catheters for management of urinary retention and collecting devices for management of urinary incontinence Luja™ SpeediCath® Flex Set SpeediCath® Navi SpeediCath® Flex • Around 6 million people live with urinary retention Intermittent catheter
Slide 85: Bowel Care
Introducing Key products Bowel Care Market fundamentals • Market size of DKK ~1bn • High-single digit market growth Peristeen® Plus Anal Irrigation Peristeen® Anal Irrigation Launched in 2021 Launched in 2003 Updated in 2011 Disease areas Faecal incontinence (management products only) Market dynamic
Slide 86: Laryngectomy
Introducing Key products - Laryngectomy Voice & Respiratory Care Provox® Life ™ Laryngectomy Heat and Moisture Exchangers (HMEs) Home Go Night Protect Energy Free hands Disease areas • People that have undergone a total laryngectomy, a typical treatment for advanced Provox® Life ™ laryngeal and hypo
Slide 87: Tracheostomy
Introducing Voice & Respiratory Care Tracheostomy Disease areas Key products - Tracheostomy • Performed when the airways are restricted, e.g., during an emergency when the airways are blocked, or when a Portfolio expansion disease or other problem makes normal breathing impossible • Strengthened the
Slide 88: Interventional Urology
Introducing Key products Interventional Urology • Men’s Health: men with erectile dysfunction. ~25% of men aged 40-70 years old experience moderate to severe erectile dysfunction. • Women’s Health: women with pelvic organ prolapse and stress urinary incontinence. ~50% of women 50- 79 years old repor
Slide 89: Advanced Wound Dressings
Key products Introducing Advanced Wound Dressings Disease areas Biatain® Silicone Non-Border Biatain® Fiber Biatain® Contact Silicone foam dressing without a Reinforced gelling fiber. Silicone contact layer. Chronic wounds border. Launched in 2021 Launched in 2020 Launched in 2019 • Leg ulcers • Dia
Slide 90: Skin Care
Introducing Key products Skin Care Disease areas • Moisture associated skin damage Sween® EasiCleanse® Bath • Incontinence Broad line of skin care products Disposable bathing wipes • Skin folds & obesity Designed to increase consistency of care Improves patient experience • Prevention of skin impair
Slide 91: US Skin Care
At a glance US Skin Care US Skin Care market Market Market drivers drivers andand limiters limiters + +AgingAging and obese population and obese population US market size estimated + +CMSCMSValueValue BasedBased Purchasing Purchasing at DKK ~5bn with 2-4% growth + +Increased focusfocus Increased on
Slide 92: The Coloplast organisation is divided into Chronic Care and Strategic Business Units
The Coloplast organisation is divided into Chronic Care and Strategic Business Units, running on shared global business support functions Coloplast Group Chronic Care Strategic Business Unit Advanced Interventional Voice & Ostomy Care Continence Care Biologics (Kerecis) Wound Dressings Urology Respi
Slide 93: The Coloplast Executive Leadership Team
The Coloplast Executive Leadership Team Kristian Villumsen President, CEO (Born 1970) With Coloplast since 2008 Nicolai Buhl Andersen Anders Lonning-Skovgaard Paul Marcun Dorthe Rønnau Allan Rasmussen EVP, Innovation EVP, CFO EVP, Growth SVP, People & Culture EVP, Operations (Born 1969) (Born 1972)
Slide 94: Income statement
Income statement DKKm FY 2021/22 FY 2022/23 Change Revenue 22,579 24,500 9% Gross profit 15,529 16,328 5% SG&A costs -7,802 -8,633 11% R&D costs -866 -872 1% Other operating income/expenses 49 22 -55% Operating profit (EBIT) before special items 6,910 6,845 -1% Special items -471 -74 -84% Operating
Slide 95: Balance sheet
Balance sheet DKKm 30 Sep 2022 30 Sep 2023 Change Balance, total 37,446 48,159 29% Assets Non-current assets 28,674 38,222 33% Current assets 8,772 9,937 13% of which: Inventories 3,187 3,522 11% Trade receivables 3,940 4,315 10% Marketable securities, cash, and cash equivalents 633 911 44% 675 Equi
Slide 96: Cash flow
Cash flow DKKm FY 2021/22 FY 2022/23 Change EBIT 6,439 6,771 5% Amortisation 260 334 28% Depreciation 670 735 10% Adjustment for other non-cash operating items 56 -220 nm Change in working capital -849 -893 5% Net interest payments -362 -769 112% Paid tax -1,115 -1,732 55% Cash flow from operations
Slide 97: Manufacturing setup
Manufacturing setup Production by country (Volume)¹ 7% 0% 3% Isafjordur Hungary 6% 0% China Hörby 10% US/France Mørdrup Tatabánya Denmark Minneapolis Nieder-Olm Nyirbátor Mankato Sarlat Zhuhai Costa Rica 75% Atos (SE/DE) Kerecis (Iceland) Costa Rica COGS by cost type² 13% 8% Salary - Direct Salary -
Slide 98: Production sites
Production sites Hungary China Tatabánya Zhuhai • Continence care products • Ostomy care products • Ostomy care products • Adhesives • Machine building • Continence care products • Number of employees in production: ~800 • Interventional Urology products • Number of employees in production: ~1,650 C
Slide 99: Production sites
Production sites France Sweden Sarlat Hörby • Disposable surgical urology products • Research & Development centre and • Number of employees in production: ~240 manufacturing of laryngectomy products • Number of employees in production: ~120 US Germany Minneapolis Nieder-Olm • Interventional Urology
Slide 100: Coloplast Sponsored Level 1 ADR programme
Coloplast Sponsored Level 1 ADR programme Coloplast Sponsored ADR Programme Benefits of a Coloplast ADR programme to US Investors: • Coloplast has established a sponsored ADR programme in the US, as a Symbol CLPBY service to US investors by offering an alternative way to trade Coloplast shares, whil
Slide 101: Contact Investor Relations
Contact Investor Relations Holtedam 1 DK-3050 Humlebæk Denmark Aleksandra Dimovska Kristine Husted Munk Senior Director, Investor Relations Senior Manager, Investor Relations Tel. direct: +45 4911 2458 Tel. direct: +45 4911 3266 Office: +45 4911 1800 Office: +45 4911 1800 dkadim@coloplast.com dkkhu@
Slide 102: Mission, values and vision
Mission Making life easier for people with intimate healthcare needs Values Closeness… to better understand Passion… to make a difference Respect and responsibility… to guide us Vision Setting the global standard for listening and responding